Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study

Hepatology

Volumn 36, Issue 6, 2002, Pages 1416-1424

  King, Jennifer K ^a   Yeh, Shiou Hwei ^b,c   Lin, Ming Wei ^d,e   Liu, Chun Jen ^f,g   Lai, Ming Yang ^f,g   Kao, Jia Horng ^f,g   Chen, Ding Shinn ^b,f   Chen, Pei Jer ^b,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INITIATION FACTOR 2; VIRUS DNA;

ADULT; ALLELE; AMPLICON; ARTICLE; CHINESE; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEPATITIS B; HEPATITIS C; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SERODIAGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS GENOME;

EID: 84983726619     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.37198     Document Type: Article

References (44)

1. World Health Organization, 1998. Hepatitis B Fact Sheet WHO/204. http://www.who.int/inf-fs/en/fact203.html
2. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-1325.
3. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-2097.
4. Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987;2:66-69.
5. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
6. Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Annu Rev Med 2001;52:29-49.
7. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
8. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
9. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
10. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207-1209.
11. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559.
12. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
13. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782.
14. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000;31:716-725.
15. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HB e antigen negative chronic hepatitis B. J Med Virol 1996;48:8-16.
16. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Lohr HF, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997;26:503-507.
17. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-1069.
18. McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL. Host-pathogen interactions in emerging and re-emerging infectious diseases: A genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu Rev Public Health 2000;21:15-46.
19. Scully LJ, Brown D, Lloyd C, Shein R, Thomas HC. Immunological studies before and during interferon therapy in chronic HBV infection: Identification of factors predicting response. Hepatology 1990;12:1111-1117.
20. Samuel CE. Antiviral actions of interferons [Table of Contents]. Clin Microbiol Rev 2001;14:778-809.
21. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
22. Clayton D, Jones H. Transmission/disequilibrium tests for extended marker haplotypes. Am J Hum Genet 1999;65:1161-1169.
23. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97-105.
24. Samuel CE. Mechanism of interferon action: Phosphorylation of protein synthesis initiation factor eIF-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc Natl Acad Sci U S A 1979;76:600-604.
25. Pathak VK, Schindler D, Hershey JW. Generation of a mutant form of protein synthesis initiation factor eIF-2 lacking the site of phosphorylation by eIF-2 kinases. Mol Cell Biol 1988;8:993-995.
26. Lindenbach BD, Rice CM, Clemens MJ. RNA in targeting an animal virus: News from the front. Initiation factor eIF2 α phosphorylation in stress responses and apoptosis. Mol Cell 2002;9:925-927.
27. Clemens MJ. Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis. Prog Mol Subcell Biol 2001;27:57-89.
28. Humbelin M, Safer B, Chiorini JA, Hershey JW, Cohen RB. Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2 α. Gene 1989;81:315-324.
29. Jacob WF, Silverman TA, Cohen RB, Safer B. Identification and characterization of a novel transcription factor participating in the expression of eukaryotic initiation factor 2 α. J Biol Chem 1989;264:20372-20384.
30. Noguchi M, Miyamoto S, Silverman TA, Safer B. Characterization of an antisense Inr element in the eIF-2 α gene. J Biol Chem 1994;269:29161-29167.
31. Silverman TA, Noguchi M, Safer B. Role of sequences within the first intron in the regulation of expression of eukaryotic initiation factor 2 α. J Biol Chem 1992;267:9738-9742.
32. Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: Revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology 2001;44:379-382.
33. Pavlovic J, Schroder A, Blank A, Pitossi F, Staeheli P. Mx proteins: GTPases involved in the interferon-induced antiviral state. Ciba Found Symp 1993;176:233-243.
34. Haller O, Frese M, Kochs G. Mx proteins: Mediators of innate re sistance to RNA viruses. Rev Sci Tech 1998;17:220-230.
35. Arnheiter H, Frese M, Kambadur R, Meier E, Haller O. Mx transgenic mice - Animal models of health. Curr Top Microbiol Immunol 1996;206:119-147.
36. Frese M, Kochs G, Meier-Dieter U, Siebler J, Haller O. Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. J Virol 1995;69:3904-3909.
37. Marschall M, Zach A, Hechtfischer A, Foerst G, Meier-Ewert H, Haller O. Inhibition of influenza C viruses by human MxA protein. Virus Res 2000;67:179-188.
38. Pavlovic J, Haller O, Staeheli P. Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. J Virol 1992;66:2564-2569.
39. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000;43:124-127.
40. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
41. Warrington JA, Shah NA, Chen X, Janis M, Liu C, Kondapalli S, Reyes V, et al. New developments in high-throughput resequencing and variation detection using high density microarrays. Hum Mutat 2002;19:402-409.
42. Huber M, Mundlein A, Dornstauder E, Schneeberger C, Tempfer CB, Mueller MW, Schmidt WM. Accessing single nucleotide polymorphisms in genomic DNA by direct multiplex polymerase chain reaction amplification on oligonucleotide microarrays. Ann Biochem 2002;303:25-33.
43. Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: An accurate detection platform for single nucleotide polymorphisms. Hum Mutat 2002;19:479-485.
44. Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2001;2:235-258.